Table of Content

1 Short-acting Recombinant Human Erythropoietin Market Overview
1.1 Product Overview and Scope of Short-acting Recombinant Human Erythropoietin
1.2 Short-acting Recombinant Human Erythropoietin Segment by Type
1.2.1 Global Short-acting Recombinant Human Erythropoietin Market Value Comparison by Type (2024-2034)
1.2.2 Epoetin-alfa
1.2.3 Epoetin-beta
1.2.4 Darbepoetin-alfa
1.2.5 Others
1.3 Short-acting Recombinant Human Erythropoietin Segment by Application
1.3.1 Global Short-acting Recombinant Human Erythropoietin Market Value by Application: (2024-2034)
1.3.2 Anemia
1.3.3 Kidney Disorders
1.3.4 Others
1.4 Global Short-acting Recombinant Human Erythropoietin Market Size Estimates and Forecasts
1.4.1 Global Short-acting Recombinant Human Erythropoietin Revenue 2018-2029
1.4.2 Global Short-acting Recombinant Human Erythropoietin Sales 2018-2029
1.4.3 Global Short-acting Recombinant Human Erythropoietin Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Short-acting Recombinant Human Erythropoietin Market Competition by Manufacturers
2.1 Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Manufacturers (2018-2024)
2.2 Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Short-acting Recombinant Human Erythropoietin Average Price by Manufacturers (2018-2024)
2.4 Global Short-acting Recombinant Human Erythropoietin Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin, Product Type & Application
2.7 Short-acting Recombinant Human Erythropoietin Market Competitive Situation and Trends
2.7.1 Short-acting Recombinant Human Erythropoietin Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Short-acting Recombinant Human Erythropoietin Players Market Share by Revenue
2.7.3 Global Short-acting Recombinant Human Erythropoietin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Short-acting Recombinant Human Erythropoietin Retrospective Market Scenario by Region
3.1 Global Short-acting Recombinant Human Erythropoietin Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Short-acting Recombinant Human Erythropoietin Global Short-acting Recombinant Human Erythropoietin Sales by Region: 2018-2029
3.2.1 Global Short-acting Recombinant Human Erythropoietin Sales by Region: 2018-2024
3.2.2 Global Short-acting Recombinant Human Erythropoietin Sales by Region: 2024-2029
3.3 Global Short-acting Recombinant Human Erythropoietin Global Short-acting Recombinant Human Erythropoietin Revenue by Region: 2018-2029
3.3.1 Global Short-acting Recombinant Human Erythropoietin Revenue by Region: 2018-2024
3.3.2 Global Short-acting Recombinant Human Erythropoietin Revenue by Region: 2024-2029
3.4 North America Short-acting Recombinant Human Erythropoietin Market Facts & Figures by Country
3.4.1 North America Short-acting Recombinant Human Erythropoietin Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2029)
3.4.3 North America Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Short-acting Recombinant Human Erythropoietin Market Facts & Figures by Country
3.5.1 Europe Short-acting Recombinant Human Erythropoietin Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2029)
3.5.3 Europe Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Short-acting Recombinant Human Erythropoietin Market Facts & Figures by Country
3.6.1 Asia Pacific Short-acting Recombinant Human Erythropoietin Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2029)
3.6.3 Asia Pacific Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Short-acting Recombinant Human Erythropoietin Market Facts & Figures by Country
3.7.1 Latin America Short-acting Recombinant Human Erythropoietin Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2029)
3.7.3 Latin America Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Short-acting Recombinant Human Erythropoietin Market Facts & Figures by Country
3.8.1 Middle East and Africa Short-acting Recombinant Human Erythropoietin Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2029)
3.8.3 Middle East and Africa Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2029)
4.1.1 Global Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024)
4.1.2 Global Short-acting Recombinant Human Erythropoietin Sales by Type (2024-2029)
4.1.3 Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
4.2 Global Short-acting Recombinant Human Erythropoietin Revenue by Type (2018-2029)
4.2.1 Global Short-acting Recombinant Human Erythropoietin Revenue by Type (2018-2024)
4.2.2 Global Short-acting Recombinant Human Erythropoietin Revenue by Type (2024-2029)
4.2.3 Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
4.3 Global Short-acting Recombinant Human Erythropoietin Price by Type (2018-2029)
5 Segment by Application
5.1 Global Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2029)
5.1.1 Global Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024)
5.1.2 Global Short-acting Recombinant Human Erythropoietin Sales by Application (2024-2029)
5.1.3 Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
5.2 Global Short-acting Recombinant Human Erythropoietin Revenue by Application (2018-2029)
5.2.1 Global Short-acting Recombinant Human Erythropoietin Revenue by Application (2018-2024)
5.2.2 Global Short-acting Recombinant Human Erythropoietin Revenue by Application (2024-2029)
5.2.3 Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
5.3 Global Short-acting Recombinant Human Erythropoietin Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Amgen Short-acting Recombinant Human Erythropoietin Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Corporation Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Roche Short-acting Recombinant Human Erythropoietin Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Kyowa Kirin
6.4.1 Kyowa Kirin Corporation Information
6.4.2 Kyowa Kirin Description and Business Overview
6.4.3 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Product Portfolio
6.4.5 Kyowa Kirin Recent Developments/Updates
6.5 LG Chem
6.5.1 LG Chem Corporation Information
6.5.2 LG Chem Description and Business Overview
6.5.3 LG Chem Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
6.5.4 LG Chem Short-acting Recombinant Human Erythropoietin Product Portfolio
6.5.5 LG Chem Recent Developments/Updates
6.6 Daewoong Pharmaceutical
6.6.1 Daewoong Pharmaceutical Corporation Information
6.6.2 Daewoong Pharmaceutical Description and Business Overview
6.6.3 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Product Portfolio
6.6.5 Daewoong Pharmaceutical Recent Developments/Updates
6.7 Wockhardt
6.6.1 Wockhardt Corporation Information
6.6.2 Wockhardt Description and Business Overview
6.6.3 Wockhardt Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Wockhardt Short-acting Recombinant Human Erythropoietin Product Portfolio
6.7.5 Wockhardt Recent Developments/Updates
6.8 CJ Healthcare
6.8.1 CJ Healthcare Corporation Information
6.8.2 CJ Healthcare Description and Business Overview
6.8.3 CJ Healthcare Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
6.8.4 CJ Healthcare Short-acting Recombinant Human Erythropoietin Product Portfolio
6.8.5 CJ Healthcare Recent Developments/Updates
6.9 3SBio
6.9.1 3SBio Corporation Information
6.9.2 3SBio Description and Business Overview
6.9.3 3SBio Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
6.9.4 3SBio Short-acting Recombinant Human Erythropoietin Product Portfolio
6.9.5 3SBio Recent Developments/Updates
6.10 Kexing Biopharm
6.10.1 Kexing Biopharm Corporation Information
6.10.2 Kexing Biopharm Description and Business Overview
6.10.3 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Product Portfolio
6.10.5 Kexing Biopharm Recent Developments/Updates
6.11 Harbin Pharmaceutical Group
6.11.1 Harbin Pharmaceutical Group Corporation Information
6.11.2 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Description and Business Overview
6.11.3 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Product Portfolio
6.11.5 Harbin Pharmaceutical Group Recent Developments/Updates
6.12 Beijing Four Rings Bio-Pharmaceutical
6.12.1 Beijing Four Rings Bio-Pharmaceutical Corporation Information
6.12.2 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Description and Business Overview
6.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Product Portfolio
6.12.5 Beijing Four Rings Bio-Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Short-acting Recombinant Human Erythropoietin Industry Chain Analysis
7.2 Short-acting Recombinant Human Erythropoietin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Short-acting Recombinant Human Erythropoietin Production Mode & Process
7.4 Short-acting Recombinant Human Erythropoietin Sales and Marketing
7.4.1 Short-acting Recombinant Human Erythropoietin Sales Channels
7.4.2 Short-acting Recombinant Human Erythropoietin Distributors
7.5 Short-acting Recombinant Human Erythropoietin Customers
8 Short-acting Recombinant Human Erythropoietin Market Dynamics
8.1 Short-acting Recombinant Human Erythropoietin Industry Trends
8.2 Short-acting Recombinant Human Erythropoietin Market Drivers
8.3 Short-acting Recombinant Human Erythropoietin Market Challenges
8.4 Short-acting Recombinant Human Erythropoietin Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Short-acting Recombinant Human Erythropoietin Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Short-acting Recombinant Human Erythropoietin Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Short-acting Recombinant Human Erythropoietin Market Competitive Situation by Manufacturers in 2022
Table 4. Global Short-acting Recombinant Human Erythropoietin Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Short-acting Recombinant Human Erythropoietin Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Short-acting Recombinant Human Erythropoietin Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Short-acting Recombinant Human Erythropoietin Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Short-acting Recombinant Human Erythropoietin, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin, Product Type & Application
Table 12. Global Key Manufacturers of Short-acting Recombinant Human Erythropoietin, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Short-acting Recombinant Human Erythropoietin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Short-acting Recombinant Human Erythropoietin as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Short-acting Recombinant Human Erythropoietin Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Short-acting Recombinant Human Erythropoietin Sales by Region (2018-2024) & (K Units)
Table 18. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Region (2018-2024)
Table 19. Global Short-acting Recombinant Human Erythropoietin Sales by Region (2024-2029) & (K Units)
Table 20. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Region (2024-2029)
Table 21. Global Short-acting Recombinant Human Erythropoietin Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Region (2018-2024)
Table 23. Global Short-acting Recombinant Human Erythropoietin Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Region (2024-2029)
Table 25. North America Short-acting Recombinant Human Erythropoietin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 27. North America Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 28. North America Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Short-acting Recombinant Human Erythropoietin Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Short-acting Recombinant Human Erythropoietin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 32. Europe Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 33. Europe Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Short-acting Recombinant Human Erythropoietin Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Short-acting Recombinant Human Erythropoietin Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Short-acting Recombinant Human Erythropoietin Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Short-acting Recombinant Human Erythropoietin Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Short-acting Recombinant Human Erythropoietin Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Short-acting Recombinant Human Erythropoietin Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Short-acting Recombinant Human Erythropoietin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Short-acting Recombinant Human Erythropoietin Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Short-acting Recombinant Human Erythropoietin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Short-acting Recombinant Human Erythropoietin Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Short-acting Recombinant Human Erythropoietin Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Short-acting Recombinant Human Erythropoietin Sales (K Units) by Type (2018-2024)
Table 51. Global Short-acting Recombinant Human Erythropoietin Sales (K Units) by Type (2024-2029)
Table 52. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2024)
Table 53. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Type (2024-2029)
Table 54. Global Short-acting Recombinant Human Erythropoietin Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Short-acting Recombinant Human Erythropoietin Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2024)
Table 57. Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2024-2029)
Table 58. Global Short-acting Recombinant Human Erythropoietin Price (US$/Unit) by Type (2018-2024)
Table 59. Global Short-acting Recombinant Human Erythropoietin Price (US$/Unit) by Type (2024-2029)
Table 60. Global Short-acting Recombinant Human Erythropoietin Sales (K Units) by Application (2018-2024)
Table 61. Global Short-acting Recombinant Human Erythropoietin Sales (K Units) by Application (2024-2029)
Table 62. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2024)
Table 63. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Application (2024-2029)
Table 64. Global Short-acting Recombinant Human Erythropoietin Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Short-acting Recombinant Human Erythropoietin Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2024)
Table 67. Global Short-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2024-2029)
Table 68. Global Short-acting Recombinant Human Erythropoietin Price (US$/Unit) by Application (2018-2024)
Table 69. Global Short-acting Recombinant Human Erythropoietin Price (US$/Unit) by Application (2024-2029)
Table 70. Amgen Corporation Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. Amgen Short-acting Recombinant Human Erythropoietin Product
Table 74. Amgen Recent Developments/Updates
Table 75. Johnson & Johnson Corporation Information
Table 76. Johnson & Johnson Description and Business Overview
Table 77. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Product
Table 79. Johnson & Johnson Recent Developments/Updates
Table 80. Roche Corporation Information
Table 81. Roche Description and Business Overview
Table 82. Roche Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Roche Short-acting Recombinant Human Erythropoietin Product
Table 84. Roche Recent Developments/Updates
Table 85. Kyowa Kirin Corporation Information
Table 86. Kyowa Kirin Description and Business Overview
Table 87. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Product
Table 89. Kyowa Kirin Recent Developments/Updates
Table 90. LG Chem Corporation Information
Table 91. LG Chem Description and Business Overview
Table 92. LG Chem Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. LG Chem Short-acting Recombinant Human Erythropoietin Product
Table 94. LG Chem Recent Developments/Updates
Table 95. Daewoong Pharmaceutical Corporation Information
Table 96. Daewoong Pharmaceutical Description and Business Overview
Table 97. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Product
Table 99. Daewoong Pharmaceutical Recent Developments/Updates
Table 100. Wockhardt Corporation Information
Table 101. Wockhardt Description and Business Overview
Table 102. Wockhardt Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Wockhardt Short-acting Recombinant Human Erythropoietin Product
Table 104. Wockhardt Recent Developments/Updates
Table 105. CJ Healthcare Corporation Information
Table 106. CJ Healthcare Description and Business Overview
Table 107. CJ Healthcare Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. CJ Healthcare Short-acting Recombinant Human Erythropoietin Product
Table 109. CJ Healthcare Recent Developments/Updates
Table 110. 3SBio Corporation Information
Table 111. 3SBio Description and Business Overview
Table 112. 3SBio Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. 3SBio Short-acting Recombinant Human Erythropoietin Product
Table 114. 3SBio Recent Developments/Updates
Table 115. Kexing Biopharm Corporation Information
Table 116. Kexing Biopharm Description and Business Overview
Table 117. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Product
Table 119. Kexing Biopharm Recent Developments/Updates
Table 120. Harbin Pharmaceutical Group Corporation Information
Table 121. Harbin Pharmaceutical Group Description and Business Overview
Table 122. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Product
Table 124. Harbin Pharmaceutical Group Recent Developments/Updates
Table 125. Beijing Four Rings Bio-Pharmaceutical Corporation Information
Table 126. Beijing Four Rings Bio-Pharmaceutical Description and Business Overview
Table 127. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Product
Table 129. Beijing Four Rings Bio-Pharmaceutical Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Short-acting Recombinant Human Erythropoietin Distributors List
Table 133. Short-acting Recombinant Human Erythropoietin Customers List
Table 134. Short-acting Recombinant Human Erythropoietin Market Trends
Table 135. Short-acting Recombinant Human Erythropoietin Market Drivers
Table 136. Short-acting Recombinant Human Erythropoietin Market Challenges
Table 137. Short-acting Recombinant Human Erythropoietin Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Short-acting Recombinant Human Erythropoietin
Figure 2. Global Short-acting Recombinant Human Erythropoietin Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Short-acting Recombinant Human Erythropoietin Market Share by Type in 2022 & 2029
Figure 4. Epoetin-alfa Product Picture
Figure 5. Epoetin-beta Product Picture
Figure 6. Darbepoetin-alfa Product Picture
Figure 7. Others Product Picture
Figure 8. Global Short-acting Recombinant Human Erythropoietin Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Short-acting Recombinant Human Erythropoietin Market Share by Application in 2022 & 2029
Figure 10. Anemia
Figure 11. Kidney Disorders
Figure 12. Others
Figure 13. Global Short-acting Recombinant Human Erythropoietin Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Short-acting Recombinant Human Erythropoietin Market Size (2018-2029) & (US$ Million)
Figure 15. Global Short-acting Recombinant Human Erythropoietin Sales (2018-2029) & (K Units)
Figure 16. Global Short-acting Recombinant Human Erythropoietin Average Price (US$/Unit) & (2018-2029)
Figure 17. Short-acting Recombinant Human Erythropoietin Report Years Considered
Figure 18. Short-acting Recombinant Human Erythropoietin Sales Share by Manufacturers in 2022
Figure 19. Global Short-acting Recombinant Human Erythropoietin Revenue Share by Manufacturers in 2022
Figure 20. The Global 5 and 10 Largest Short-acting Recombinant Human Erythropoietin Players: Market Share by Revenue in 2022
Figure 21. Short-acting Recombinant Human Erythropoietin Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 22. Global Short-acting Recombinant Human Erythropoietin Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 23. North America Short-acting Recombinant Human Erythropoietin Sales Market Share by Country (2018-2029)
Figure 24. North America Short-acting Recombinant Human Erythropoietin Revenue Market Share by Country (2018-2029)
Figure 25. United States Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Canada Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Europe Short-acting Recombinant Human Erythropoietin Sales Market Share by Country (2018-2029)
Figure 28. Europe Short-acting Recombinant Human Erythropoietin Revenue Market Share by Country (2018-2029)
Figure 29. Germany Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. France Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. U.K. Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Italy Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Russia Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Asia Pacific Short-acting Recombinant Human Erythropoietin Sales Market Share by Region (2018-2029)
Figure 35. Asia Pacific Short-acting Recombinant Human Erythropoietin Revenue Market Share by Region (2018-2029)
Figure 36. China Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Japan Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. South Korea Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. India Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Australia Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. China Taiwan Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Southeast Asia Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Latin America Short-acting Recombinant Human Erythropoietin Sales Market Share by Country (2018-2029)
Figure 44. Latin America Short-acting Recombinant Human Erythropoietin Revenue Market Share by Country (2018-2029)
Figure 45. Mexico Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Brazil Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Argentina Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Colombia Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Short-acting Recombinant Human Erythropoietin Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Short-acting Recombinant Human Erythropoietin Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. UAE Short-acting Recombinant Human Erythropoietin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Short-acting Recombinant Human Erythropoietin by Type (2018-2029)
Figure 55. Global Revenue Market Share of Short-acting Recombinant Human Erythropoietin by Type (2018-2029)
Figure 56. Global Short-acting Recombinant Human Erythropoietin Price (US$/Unit) by Type (2018-2029)
Figure 57. Global Sales Market Share of Short-acting Recombinant Human Erythropoietin by Application (2018-2029)
Figure 58. Global Revenue Market Share of Short-acting Recombinant Human Erythropoietin by Application (2018-2029)
Figure 59. Global Short-acting Recombinant Human Erythropoietin Price (US$/Unit) by Application (2018-2029)
Figure 60. Short-acting Recombinant Human Erythropoietin Value Chain
Figure 61. Short-acting Recombinant Human Erythropoietin Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed